Kinnate Biopharma (KNTE) Social Stream



Kinnate Biopharma (KNTE): $2.60

0.13 (+5.26%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add KNTE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#100 of 356

in industry

KINNATE BIOPHARMA INC (KNTE) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering KINNATE BIOPHARMA INC.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-10-28 6 $52 $32 $46.4 $2.49 1763.45%
2021-11-11 6 $53 $32 $47 $2.49 1787.55%
2022-02-02 6 $52 $35 $45.8 $2.49 1739.36%
2022-03-29 6 $52 $33 $42 $2.49 1586.75%
2022-05-12 6 $52 $33 $41 $2.49 1546.59%
2022-05-13 6 $52 $33 $39.8 $2.49 1498.39%
2022-05-18 6 $46 $30 $35.4 $2.49 1321.69%
2022-07-27 7 $46 $29 $34.333 $2.49 1278.84%
2022-10-26 8 $46 $29 $34.142 $2.49 1271.16%
2022-11-11 8 $46 $29 $33.571 $2.49 1248.23%
2023-02-07 8 $46 $11 $30.142 $2.49 1110.52%
2023-02-26 8 $36 $11 $28.714 $2.49 1053.17%
2023-04-17 8 $36 $8 $27.714 $2.49 1013.01%
2023-04-19 8 $36 $5 $23.714 $2.49 852.37%
2023-05-11 8 $36 $5 $21.142 $2.49 749.08%
2023-05-12 8 $36 $5.4 $21.2 $2.49 751.41%
2023-08-09 8 $36 $5.4 $21.057 $2.49 745.66%
2023-08-15 8 $31 $5.4 $20.342 $2.49 716.95%
2023-09-19 8 $26 $2 $7.233 $2.49 190.48%
2023-11-09 8 $26 $1.5 $6.583 $2.49 164.38%

The Trend in the Analyst Price Target


KNTE's average price target has moved down $44.42 over the prior 27 months.

KNTE reports an average of 506.5% for its upside potential over the past 39 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-02-26 8 36 11.0 28.714 5.18 454.32%
2023-04-19 8 36 5.0 23.714 3.34 610%
2023-05-12 8 36 5.4 21.200 3.77 462.33%
2023-08-09 8 36 5.4 21.057 2.66 691.62%
2023-09-19 8 26 2.0 7.233 1.50 382.2%

KNTE Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2 4 0 4 0 0 8

The Trend in the Broker Recommendations


Over the past 21 months, KNTE's average broker recommendation rating worsened by 1.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • In terms of how KINNATE BIOPHARMA INC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is greater than 2025.71% of that group.
  • KNTE has a greater number of analysts covering the stock than 1734.11% of stocks in the small market cap category.
  • KNTE has a lower variance in analysts' estimates than -1063.72% of Pharmaceutical Products stocks.
  • In the context of stocks in the small market cap category, KINNATE BIOPHARMA INC's average analyst price target is greater than 1455.54% of them.

Stocks similar to KINNATE BIOPHARMA INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are LABP, SNSE, and PHVS.

What is the outlook for KNTE? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!